Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
Heitmann JS, Tandler C, Marconato M, Nelde A, Habibzada T, Rittig SM, Tegeler CM, Maringer Y, Jaeger SU, Denk M, Richter M, Oezbek MT, Wiesmüller KH, Bauer J, Rieth J, Wacker M, Schroeder SM, Hoenisch Gravel N, Scheid J, Märklin M, Henrich A, Klimovich B, Clar KL, Lutz M, Holzmayer S, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Peuker CA, Habringer S, Goetze TO, Jäger E, Rammensee HG, Salih HR, Walz JS. Heitmann JS, et al. Among authors: richter m. Nat Commun. 2023 Aug 18;14(1):5032. doi: 10.1038/s41467-023-40758-0. Nat Commun. 2023. PMID: 37596280 Free PMC article. Clinical Trial.
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.
Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, Reusch J, Jäger S, Denk M, Richter M, Anton L, Weber LM, Roerden M, Bauer J, Rieth J, Wacker M, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Karbach J, Jäger E, Klein R, Rammensee HG, Salih HR, Walz JS. Heitmann JS, et al. Among authors: richter m. Nature. 2022 Jan;601(7894):617-622. doi: 10.1038/s41586-021-04232-5. Epub 2021 Nov 23. Nature. 2022. PMID: 34814158 Free PMC article. Clinical Trial.
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, Zwick M, Dicks S, Nelde A, Dubbelaar M, Scheid J, Wacker M, Heitmann JS, Schroeder S, Rieth J, Denk M, Richter M, Klein R, Bonzheim I, Luibrand J, Holzer U, Ebinger M, Brecht IB, Bitzer M, Boerries M, Feucht J, Salih HR, Rammensee HG, Hailfinger S, Walz JS. Bauer J, et al. Among authors: richter m. Nat Commun. 2022 Oct 27;13(1):6401. doi: 10.1038/s41467-022-33746-3. Nat Commun. 2022. PMID: 36302754 Free PMC article.
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.
Tandler C, Heitmann JS, Michel TM, Marconato M, Jaeger SU, Tegeler CM, Denk M, Richter M, Oezbek MT, Maringer Y, Schroeder SM, Schneiderhan-Marra N, Wiesmüller KH, Bitzer M, Ruetalo N, Schindler M, Meisner C, Fischer I, Rammensee HG, Salih HR, Walz JS. Tandler C, et al. Among authors: richter m. Int J Infect Dis. 2024 Feb;139:69-77. doi: 10.1016/j.ijid.2023.11.009. Epub 2023 Nov 26. Int J Infect Dis. 2024. PMID: 38016500 Free article.
2,784 results